Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Brain Cancer
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Phase 2 Trial Using IL-12 Gene Therapy for Glioblastoma Reaches Recruitment Target
A new approach combining inducible gene therapy and an anti–PD-1 shows promise in hard-to-treat brain tumors.
The Twitter Effect on How Oncologists Conduct and Share Research
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
Conflicts of Interest Continue to Plague Oncology Guidelines and Research
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
FDA Grants Orphan Drug Status to Berubicin for Malignant Gliomas
he designation is supported by data from a phase 1 trial conducted by Reata Pharmaceuticals in 2016. Findings from the study showed 44% of patients treated with berubicin (n=11 out of 25) experienced a statistically significant improvement in progression free survival.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
-
Loading...
-
Loading...
Next post in General Oncology
